pofol has been associated with a low incidence of postoperative nausea and vomiting (PONV), compared with inhaled anesthetics. [8] Some studies suggest that propofol acts as an antiemetic when it is used to treat chemotherapy-induced emesis [9] and PONV in subhypnotic doses. [10, 11] Major breast surgery is associated with a high incidence of PONV. [12] A previous study found that the incidence of nausea and vomiting is as high as 60% and that most of these symptoms occur after patients leave the postoperative care unit. [13] Incidence rates of PONV in women are approximately two to three times greater than in men, [14] and the severity of vomiting is also greater in women. [15] Using one or the other method with an objective monitor to reduce the incidence of side effects such as PONV and quality of anesthesia in patient undergoing breast surgery is lacking.
We hypothesized that total i.v. anesthesia with propofol might reduce the incidence of PONV and improve patient well-being and satisfaction. This randomized, prospective study was designed to assess the effects of total i.v. anesthesia with propofol compared with inhalational anesthesia with sevoflurane on patients undergoing breast surgery. Postoperative well-being and major adverse events in the postoperative period were recorded.
METHODS
This trial was approved by the ethical review committee of Chang Gung Memorial Hospital (CGMHIRB no. 99-3537A3) in accordance with the 2008 Declaration of Helsinki, and informed consent was obtained from every patient prior to participation in the trial.
Patients
A total of 84 patients undergoing elective breast surgery from 1 to 4 h in duration between March 2011 and December 2011 were prospectively included in the study. Exclusion criteria were: (1) refusal or inability to provide informed consent, (2) age less than 20 years or more than 70 years, smoking status, (3) allergy to intravenous propofol, (4) pregnancy, (5) gastrointestinal disease, (6) a history of motion sickness or a previous episode of PONV, (7) had received any steroid or antiemetic medication within 24 h before surgery, (8) or an ASA grade equal to or greater than 3. Associated medical illnesses were graded according to the American Society of Anesthetists' Physical Status Classification (ASA grade).
Study design

Randomization
All participants were randomly assigned to the TIVA group (total intravenous anesthesia with propofol) or the SEVO group (inhalational anesthesia with sevoflurane) using a concealed allocation approach (computer-generated codes) utilizing opaque, sealed envelopes containing the randomization schedule. These envelopes were opened immediately before induction of anesthesia.
Personnel in the post-anesthesia care unit (PACU), including the physician on duty, remained blinded to the randomization. Intravenous lines and stopcocks were flushed with saline to remove any visible trace of propofol before transporting patients to the PACU. All patients received oxygen via oxygen mask for at least 30 min after arrival in the PACU. This served to camouflage the odor of residual sevoflurane in expired air.
Research nurses who made intraoperative and postoperative observations were not involved in the care-giving process. During the patients' stay in the PACU, the anesthesia record was kept in a sealed envelope to be opened only in case of emergency by the research nurse who had performed the intraoperative observations. Patients were blinded to the anesthetic technique at all times during the study.
Intraoperative settings
All patients were unpremedicated. Before induction of anesthesia, electrocardiography (ECG), pulse oximetry, and noninvasive blood pressure monitoring were applied and three A-Line ® Auditory evoked potential (AEP) electrodes (Danmeter, Odense, Denmark) were positioned at the mid-forehead (+), left forehead (reference), and left mastoid (−). In the TIVA group, anesthesia was induced with 2 mcg/kg fentanyl, 2% lidocaine (0.5 mg/kg), and cisatracurium (0.2 mg/kg). Afterward, continuous infusion of propofol was begun by using a target-controlled infusion (TCI) system (Fresenius Orchestra Primea ® , Fresenius Kabi AG, Bad Homburg, Germany) with the plasma target set (plasma mode drive = Cp) at 5.0 mcg/ ml in Schneider mode. When the patient lost consciousness, the trachea was intubated until the AEP index (AAI) decreased to 20 and mechanical ventilation was then started. The anesthesia was maintained using TCI with propofol and a gas flow of 0.5 l/min oxygen mixed with 0.5 l/min air. In the SEVO group, anesthesia was induced with 2 mcg/kg fentanyl, 2% lidocaine (0.5 mg/ kg), cisatracurium (0.2 mg/kg), and 2 mg/kg propofol. After the loss of consciousness, tracheal intubation was performed until the AAI decreased to 20. The anesthesia was maintained with SEVO in 1 l/min oxygen mixed with air. Partial oxygen saturation (SpO 2 ), mean blood pressure (MBP), and heart rate (HR) were monitored and recorded at the preinduction (baseline), 1 min intervals during induction of anesthesia, and subsequently at 5 min intervals throughout the anesthesia and recovery periods. HR was measured using a continuous lead type II ECG; MBP was measured noninvasively using an automatic oscillometer and SpO 2 was measured by pulse oximetry. Respiratory monitors included respiratory rate (RR), SpO 2 , and end-tidal carbon dioxide by capnometry.
During maintenance of anesthesia, propofol and sevoflurane were adjusted continuously to keep the AAI between 15 and 25. Adverse hemodynamic responses of about 1 min duration were recorded and classified as "hypertension" (MBP > 20% above preoperative baseline value), "hypotension" (MBP < 60 mmHg), "tachycardia" (HR > 20% above preoperative baseline value), or "bradycardia" (HR < 50 beats/min). The concentrations of propofol and sevoflurane were adjusted according to patient's vital sign and AAI value every 1 min, when adverse hemodynamic responses happen. If the AAI was over 25 and associated with hypertension and tachycardia, it was initially treated by concentration of effect (Ce) with 0.2 mcg/ml and 0.2% increments of propofol and sevoflurane, respectively. If two increments were unsuccessful, propofol and sevoflurane were increased by 0.5 mcg/ml and 0.5% increments, respectively, until the AAI was between 15 and 25. Hypertension and tachycardia were treated with fentanyl (1 mcg/kg i.v.) if the AAI was in the set range. If fentanyl did not work, hypertension with normal sinus rhythm was treated with nicardipine (10 µg/kg) or hypertension with tachycardia was treated with labetalol (5 mg). If the AAI was less than 15 and associated with hypotension, we applied 0.2 mcg/ml and 0.2% decrements in propofol and sevoflurane, respectively. If two decrements were unsuccessful, propofol and sevoflurane were decreased by 0.5 mcg/ml and 0.5% decrements, respectively, until the AAI was between 15 and 25. Hypotension was treated initially with fluids and 4 mg ephedrine was given intravenously if the AAI was in the set range. Atropine (0.5 mg) was given if the HR decreased to < 50 beats/min and was accompanied by hypotension.
Respiratory frequency and end-tidal volume were adjusted to maintain the ETCO 2 at 32-35 mmHg. The i.v. fluid administration during operation in each patient was calculated on the basis of body weight, fasting time, blood loss, and maintenance fluid requirement. One hour following the initial dose of cisatracurium, muscle relaxation was maintained with cisatracurium 0.03 mg/kg/30 min i.v. as a bolus dose, until 30 min before emergence. At the last 10 stitches of surgery, administration of the maintenance anesthetics was discontinued and the oxygen flow was adjusted to 6 l/min. Muscle relaxation was reversed with intravenous neostigmine (2.5 mg) combined with atropine (1 mg). Extubation was performed with RR less than 25 breaths/min, spontaneous tidal volume greater than 5 ml/kg, inspiratory force of at least -20 cm H 2 O, vital capacity at least 10 ml/kg, and the ability of the patient to open the eyes by verbal command. Emergence from anesthesia was assessed by measuring the time until removal of the endotracheal tube.
Measurement protocol
Preoperative measurements
A research nurse recorded the baseline characteristics of consenting patients, including information on age, height, weight, and general health.
Intraoperative measurements
Intraoperatively, the following data were recorded: Doses and duration of induction, type and doses of all the medication administered intraoperatively, total amount of perioperative fluid, and surgical time. Time to awakening (response to verbal command) and time to extubation after discontinuation of anesthesia were recorded.
Postoperative measurements
Time to permission for discharge from the PACU was recorded. The intensity of pain was assessed using a visual analogue scale (VAS) based on a total score between 0 and 10 (0 = no pain and 10 = worst pain). If the intensity of postoperative pain was more than 4, ketorolac 30 mg was immediately given intravenously. Approximately 24 h after surgery, another member of the nursing staff who was unaware of the study visited inpatients in the ward to record the occurrence of PONV and the presence of possible postoperative side effects subsequent to discharge from the PACU. Total admission days were also recorded.
Statistical analysis
The sample size was calculated using G-power 3.1.2 software. A pilot study of 15 cases per group suggested 13% and 40% of PONV rates in TIVA and SEVO groups, respectively. A power calculation (α = 0.05 and β = 0.2) indicated that a minimum sample size of 41 patients for each group would be necessary to achieve the desired level of statistical power.
Data were analyzed using the SPSS version 19.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous data were analyzed using two-sample t-test. Discrete data were analyzed using Pearson's Chi-square or Fisher's exact tests. In all cases, a p < 0.05 was considered to be statistically significant.
RESULTS
Baseline characteristics and intraoperative data
In total, 84 patients were recruited to participate in the study. There were no significant differences in demogr aphic characteristics between the two groups [ Table 1 ]. There were also no significant differences between the groups in terms of hemodynamics, blood loss, or AEP levels (data not shown). Table 2 shows the intraoperative data. There were no statistically significant differences in the intubation time, duration of surgery, perioperative fluid management, and extubation time after TIVA or sevoflurane. The time for which the patients stayed at the PACU was similar between the two groups. Table 3 shows the amounts of intraoperative anesthetic drugs used in the two groups. There were no significant differences between the groups in the amounts of muscle relaxants and opioids used. Table 4 shows the postoperative side effects after general anesthesia in the two groups. The cumulative 24-h incidence of PONV was significantly less frequent in the TIVA group, which was only 14.3% of patients in the TIVA group compared with 50% patients in the SEVO group. We separated PONV into postoperative nausea or vomiting. Whether postoperative nausea or postoperative vomiting, the incidence was less frequent in the TIVA group than in the SEVO group. There was no significant difference between the groups in the requirements of postoperative analgesic agents. The total cost of anesthetic drugs was significantly higher in the SEVO group [ Table 5 ].
Postoperative data
DISCUSSION
A number of studies have compared general anesthesia with i.v. propofol and sevoflurane. [4] [5] [6] [16] [17] [18] [19] [20] [21] Previous studies were performed for different types of surgery [5, 16, 21, 22] and in difference patient groups. [4, 6, 7, 20] Patients undergoing breast surgery generally have a very high incidence of postoperative nausea or vomiting. [13, 15] Here, we applied AEP monitoring as a guide to titrate the level of anesthesia. AEP monitoring was more precise than in previous studies that used titrate analysis of the different anesthetics according to the hemodynamic responses to pain during anesthesia, and therefore, it is easy to err on maintaining the patients deeply anesthetized, which in turn affects recovery. [19] Thus, this study was designed to compare TIVA propofol with inhalational anesthesia under AEP monitoring in female patients undergoing breast surgery.
The primary clinical outcome that differed signifi- All values are presented as mean±SD and analyzed using two-sample t-test, Abbreviations: Time to intubation: Time from induction until successful insertion of the endotracheal tube; Time to extubation: Time from discontinuation of anesthesia until response to a verbal command and removal of the endotracheal tube; TIVA group: Total intravenous anesthesia with propofol; SEVO group: Inhalational anesthesia with sevoflurane and propofol induction Values are shown as mean±SD, There were no significant differences between the groups in the amounts of muscle relaxants and opioids used, Abbreviations: TIVA group: Total intravenous anesthesia with propofol; SEVO group: Inhalational anesthesia with sevoflurane and propofol induction cantly between groups was postoperative nausea or vomiting, which was more frequent in patients who received sevoflurane for maintenance of anesthesia and less frequent in those receiving propofol. Similar findings have been reported previously, [4] and the results are compatible with the suspected antiemetic effects of propofol. Nonetheless, propofol was recently found to possess direct antiemetic properties, and this effect is not due to the intralipid emulsion in the formulation of propofol. [23] Several studies found a low incidence of PONV when propofol was used throughout the procedure. [24] [25] [26] [27] [28] The protective effect of propofol against PONV seemed to disappear when it was used as an induction agent only. [29, 30] Thus, it is possible that a therapeutic range of plasma concentrations of propofol may be related to PONV protection.
Some studies suggest that an increase of opioids increases the risk of nausea and vomiting. [31, 32] However, the mechanisms of opioids are complex. [33] Low-dose opioids for induction of anesthesia (1.5 mcg/kg fentanyl) led only to a small increase in PONV incidence, and the increase was not statistically significant. [34] Therefore, further research in this field is warranted to clarify this issue. While data on the impacts of opioids given intraoperatively are controversial, several studies suggest that the use of postoperative opioids increases the risk of PONV. [15, 34, 35] Thus, we chose nonsteroidal anti-inflammatory drugs (if the intensity of postoperative pain was more than VAS 4, ketorolac 30 mg was immediately given intravenously) as postoperative analgesic agents, which have been shown to decrease PONV, compared with opioids, in numerous studies. [36, 37] Another important finding was that extubation times were similar in the TIVA group and the SEVO group (13.38 vs. 13.02 min, respectively). The end-tidal sevoflurane concentration of tracheal extubation was 0.33 ± 0.10%, which was not different from that observed in our clinical practice. Several studies have claimed that patients who received sevoflurane were extubated at an earlier stage than those receiving propofol, and the times to eye opening were also shorter. [6, 16] This difference can be explained in part by the proximity of AEP which could monitor anesthetic depth. The use of APE may improve the ability of anesthesiologists to titrate anesthetic drugs and contribute to a faster recovery from general anesthesia. [38] There is a limitation that needs to be acknowledged and addressed regarding the present study. Although there were no significant differences between the groups in terms of surgical duration (p = 0.06) in our study, duration of surgery is a known relative predictor for PONV, with the risk increasing proportionately after 90 min. [39, 40] Therefore, additional studies on the side effects of patients undergoing breast surgery are clearly needed to determine the role of the duration of surgery in clinical practice.
In addition, in the era of economic management of health care, it is necessary to identify the best and most cost-effective anesthetic techniques. At the same time, cost control is of major importance in today's climate of economic consciousness and the choice of anesthetic can have a significant impact on the total costs for an anesthesia department. We have shown the direct cost of sevoflurane used in the maintenance of anesthesia to be significantly higher than that of a propofol-based anesthetic [ Table 5 ], while achieving a similar outcome in terms of emergent and recovery times [ Table 2 ]. The higher incidence of PONV in the inhalational anesthetic group may also have increase the indirect costs [17] as the management of vomiting may involve using more disposable items (e.g., bowls, bedding, etc.). PONV may increase recovery staff activities, but this is unlikely to increase the costs unless the number of staff required is altered. PONV also significantly delays discharge times, and therefore, propofol-based anesthesia could shorten the duration of stay, therefore reducing the direct costs. [17] In conclusion, when compared with sevoflurane, we have shown that propofol used for the maintenance of general anesthesia improves postoperative patient well-being and reduces the incidence of PONV. Furthermore, total i.v. anesthesia with propofol also reduces costs. Thus, total i.v. anesthesia with propofol is better than sevoflu- 
